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INTRODUCTION 
The ultimate goal of personalized medicine is to provide a 
patient with the ideal treatment, optimized to the patient’s individual 
genome, to promote effective, efficient, and tailored care.1 
Developments in the sciences over the past seventy-five years have 
started making widespread personalized medicine a reality.2 For 
example, breast cancers with high expression of human epidermal 
growth factor receptor 2 (“HER2”) were associated with poor patient 
 
 *  © 2017 Leland L. Black, B.S., University of Florida, Microbiology, 2007; PhD, 
University of Alabama at Birmingham, Microbiology, 2014. 
 1. See Andrea D. Eckhart, Kirk Beebe & Mike Milburn, Metabolomics as a Key 
Integrator for “Omic” Advancement of Personalized Medicine and Future Therapies, 5 
CLINICAL & TRANSLATIONAL SCI. 285, 285 (2012).  
 2. See infra Section I.A. 
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prognoses due to faster growth and spread.3 Throughout the 1990s, 
researchers developed monoclonal antibodies to target HER2, 
slowing the growth of HER2-positive breast cancers.4 Now there are 
drugs on the market, such as trastuzumab (Herceptin), given 
specifically to patients with HER2-positive breast cancer in 
combination with chemotherapy.5 This treatment regimen, 
personalized to the patient’s genome, has nearly doubled the average 
time before a relapse and doubled the number of patients who have 
no evidence of tumor progression up to twelve months after 
treatment.6 
However, the realities and difficulties associated with 
personalized drug development remain. Imagine that a 
pharmaceutical company would have to spend fifteen years and 
hundreds of millions, even billions, of dollars perfecting techniques 
for diagnosing and treating an aggressive cancer.7 What if a patent 
was no longer a viable option to protect and recoup the company’s 
investment? What if, as a result, the lab across the street could 
reverse engineer the company’s work with minimal time and effort? 
Would the company even start the work in the first place? 
The drug development process begins in the laboratory, where 
researchers perform fundamental research to understand diseases, 
identify associated potential therapeutic targets, and find promising 
lead compounds that could be developed into new medicines.8 
Following the U.S. Food and Drug Association (the “FDA”) 
approval of a New Drug Application,9 Phase I clinical trials are 
conducted on a small number of healthy volunteers to assess the 
 
 3. A Story of Discovery: HER2’s Genetic Link to Breast Cancer Spurs Development 
of New Treatments, NAT’L CANCER INST., http://www.cancer.gov/research/progress
/discovery/HER2 [https://perma.cc/9LWY-QZKP]. 
 4. Id. 
 5. Id. 
 6. See id. 
 7. See infra note 1 and accompanying text. 
 8. PHRMA, BIOPHARMACEUTICAL RESEARCH AND DEVELOPMENT: THE 
PROCESS BEHIND NEW MEDICINES 2–4 (2015), http://phrma.org/sites/default/files/pdf/rd
_brochure.pdf [https://perma.cc/S9CQ-7U7D]. After the initial testing phase, researchers 
test the drugs utilizing various models to prioritize lead compounds and those “that 
survive the initial screening are then ‘optimized,’ or altered to make them more effective 
and safer.” Id. at 7. 
 9. The New Drug Application “is the vehicle through which drug sponsors formally 
propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.” 
New Drug Application (NDA), U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs
/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications
/NewDrugApplicationNDA/ [https://perma.cc/W7J4-XHUJ].  
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safety, bioavailability, and metabolism of the candidate drug.10 
Finally, Phase II and III clinical trials assess the safety and efficacy of 
the candidate drug in large cohorts of patients with the disease of 
interest.11 When the development process concludes, a company 
could have invested upwards of $2.6 billion and a minimum of ten 
years of labor to get a single successful drug to market.12 
Intellectual property rights, particularly patents, are key in 
allowing pharmaceutical companies to get a return on their research 
and development investments. Patents grant patentees “the right to 
exclude others from making, using, offering for sale, or selling the 
invention throughout the United States,”13 typically for a period of 
twenty years from the date of filing.14 The idea that patent protection 
is a requirement is so ingrained in the industry that “pharmaceutical 
companies systematically screen their drug candidates to exclude the 
ones lacking strong patent protection, checking their patentability at 
least three different times during drug development.”15 The last check 
typically occurs before clinical trials, and if there are any major 
threats to patentability, the drug may be pulled.16 Additionally, now 
pharmaceutical companies must ensure that defensible patents 
protect their drugs, as the rise of generic manufacturer challenges 
since the mid-1990s has dramatically increased the amount of 
pharmaceutical patent litigation in the United States.17 After a brand 
name company brings an infringement suit, the generic company will 
invariably argue that the patent in question is invalid.18 
In order to be eligible for patent protection, an invention must be 
useful,19 novel,20 and non-obvious.21 While novelty and non-
obviousness are needed for patentability, this Comment will focus on 
the statutory requirement of “usefulness” in 35 U.S.C. §	101, which 
states: “Whoever invents or discovers any new and useful process, 
 
 10. PHRMA, supra note 8, at 13. 
 11. See id. 
 12. Id. at 1. 
 13. 35 U.S.C. §	154(a)(1) (2015). 
 14. Id. §	154(a)(2). However, design patents run for fourteen years from the date of 
issue. Id. §	173 (stating that design patents run for a “term of fourteen years from the date 
of grant”). 
 15. Benjamin N. Roin, Unpatentable Drugs and the Standards of Patentability, 87 TEX. 
L. REV. 503, 545 (2009). 
 16. See id. at 546–47. 
 17. See id. at 550 & n.251.  
 18. See id. 
 19. See 35 U.S.C. §	101 (2012). 
 20. See id. §	102. 
 21. See id. §	103. 
95 N.C. L. REV. 493 (2017) 
496 NORTH CAROLINA LAW REVIEW [Vol. 95 
machine, manufacture, or composition of matter, or any new and 
useful improvement thereof, may obtain a patent therefor, subject to 
the conditions and requirements of this title.”22 Historically, an 
invention could be considered useful—directed to patent eligible 
subject matter—if it was “anything under the sun that [was] made by 
man.”23 However, during the past four years, the scope of what is 
considered patent eligible subject matter has been shrinking.24 Patent 
applications directed solely to natural phenomena and laws of nature 
have never been patent eligible,25 but a recent shift in the Court’s 
interpretation of what is “directed to” natural phenomena and laws of 
nature,26 and subsequent agency guidance, has been deemed a serious 
threat to biotech patents.27 This shift can be seen in two recent 
Supreme Court opinions—Mayo Collaborative Services v. Prometheus 
Laboratories, Inc.28 and Association for Molecular Pathology v. 
Myriad Genetics, Inc.29—and the United States Patent & Trademark 
Office’s (the “USPTO”) attempts to provide guidance and ensure 
compliance with said decisions.30 Thus, the relationship between the 
usefulness standard and personalized medicine patents, which are 
typically directed in part to measuring something naturally present in 
the body, is ripe for discussion. 
The developing restrictions on the patentability of biotech 
patents will unfortunately affect the progress of personalized 
medicine, if they have not already.31 Incentives for companies to 
spend time and effort developing advancements in personalized 
medicine, specifically a company’s ability to protect its research and 
development investments through patents, are sure to decline in the 
 
 22. Id. at §	101 (emphasis added). 
 23. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 
 24. See infra Section II.B. 
 25. 2014 Interim Eligibility Guidance Quick Reference Sheet, U.S. PAT. & 
TRADEMARK OFF., https://www.uspto.gov/patents/law/exam/myriad-mayo_qrs.pdf [https://
perma.cc/N456-G4PV]. 
 26. See infra Part II. 
 27. See generally Gene Quinn, Erosion of Patent Rights Will Harm US Economy, IP 
WATCHDOG (Aug. 28, 2014), http://www.ipwatchdog.com/2014/08/28/erosion-of-patent-rights
-will-harm-us-economy/id=50136/ [https://perma.cc/Y4PK-C97J (staff-uploaded archive)] 
(predicting that “[b]y the time Congress figures it out things will have gotten worse, 
perhaps catastrophically bad”). 
 28. 132 S. Ct. 1289 (2012). 
 29. 133 S. Ct. 2107 (2013). 
 30. The USPTO issues guidance memos to assist patent examiners in the eligibility 
analysis of patent applications. See, e.g., U.S. PATENT & TRADEMARK OFFICE, SUBJECT 
MATTER ELIGIBILITY EXAMPLES: LIFE SCIENCES, 1–28 (2016), https://www.uspto.gov
/sites/default/files/documents/ieg-may-2016-ex.pdf [https://perma.cc/YTK8-2PBG].  
 31. See infra Section I.A. 
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near future.32 It is worth noting that the decisions from the Supreme 
Court and Federal Circuit that will be discussed in this Comment are 
in direct conflict with current health care initiatives promoted by the 
other branches of the federal government.33 As the American Bar 
Association’s Section of Intellectual Property Law chair recently 
stated, “At the same time that the President and Congress are calling 
for incentives to personalized medicine innovators, the Interim 
Guidance and the Courts are placing burdens on these same 
innovators by broadly interpreting 35 U.S.C. §	101.”34 
In order to avoid drafting a personalized medicine patent 
directed to non-eligible subject matter, drafters typically include an 
“active treatment” step.35 Specifically, the first few steps of the patent 
will require screening for a biomarker,36 while the subsequent steps 
will be directed to treating the patient based on the results of the 
screening.37 In method patents38 such as these, multiple people usually 
perform the steps of the patent: a technician runs the test, a doctor 
prescribes the treatment, and a patient takes the medicine. Thus, in a 
personalized medicine infringement case, the infringement is usually 
divided among the multiple actors. Prior to a recent line of cases, a 
 
 32. See, e.g., Christopher M. Holman, The Critical Role of Patents in the Development, 
Commercialization, and Utilization of Innovative Genetic Diagnostic Tests, CTR. FOR 
PROTECTION OF INTELL. PROP., July 2014, at 3, http://cpip.gmu.edu/wp-content/uploads
/2014/04/Holman-Critical-Role-of-Patents-in-Genetic-Diagnostic-Tests.pdf [https://perma
.cc/MQ7H-6XT9]. 
 33. See Letter from Lisa A. Dunner, Section Chair, Am. Bar Ass’n, Section of 
Intellectual Prop. Law, to the Honorable Michelle Lee, Under Sec’y of Commerce for 
Intellectual Prop. and Dir. of the U.S. Patent and Trademark Office, 4–5 (March 12, 2015), 
https://www.uspto.gov/sites/default/files/documents/2014ig_a_aba_2015mar12.pdf [https://
perma.cc/62PV-7FLC]. 
 34. Id. at 4. 
 35. See Duane C. Marks, Patent Counsel, Roche Diagnostics Operations, Inc., 
Diagnostic Method Patents: A Framework for Patent-Eligibility of Diagnostic Method 
Patents Post-Mayo, Presentation at the Subject Matter Eligibility Forum 8 (May 9, 2014), 
http://www.uspto.gov/sites/default/files/patents/announce/may9forum_marks.pdf [https://
perma.cc/4MUG-22A6]; see also Bilski v. Kappos, 561 U.S. 593, 601–11 (2010) (describing 
how courts have examined cases where the subject matter eligibility of a patent was in 
question). 
 36. NCI Dictionary of Cancer Terms, NAT’L CANCER INST., http://www.cancer.gov
/publications/dictionaries/cancer-terms?cdrid=45618 [http://perma.cc/5VZK-CDQV] (defining 
a biomarker as “[a] biological molecule found in blood, other body fluids, or tissues that is 
a sign of a normal or abnormal process, or of a condition or disease”). 
 37. Classen Immunotherapies v. Biogen IDEC, 659 F.3d 1057, 1084 (Fed. Cir. 2011). 
 38. Patentable subject matter includes processes, machines, articles of manufacture, 
and compositions of matter. 35 U.S.C. §	101 (2012). Process patents are also referred to as 
method patents. BMC Res., Inc. v. Paymentech, L.P., 498 F.3d 1373, 1379 (Fed. Cir. 2007), 
overruled by Akami Techs., Inc. v. Limelight Networks, Inc., 692 F.3d 1301 (Fed. Cir. 
2012) (en banc). 
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patent directed to multiple actors could only be infringed if there was 
proof of direct infringement and a single party had exercised control 
or discretion over every step of the claimed method.39 Recently the 
Federal Circuit and the Supreme Court addressed situations of 
divided infringement—in Limelight I,40 Limelight II,41 and Limelight 
III42—and took a patentee’s ability to protect a typical personalized 
medicine patent directed to multiple actors on a roller coaster ride.43 
Following the changes to subject matter eligibility, and before 
Limelight III,44 pharmaceutical companies were on the verge of 
having to choose between not protecting their advances in 
personalized medicine due to subject matter ineligibility or receiving 
patents that could not be infringed due to the loophole in the law. In 
Limelight III, the Federal Circuit clarified the requirements to bring 
an infringement claim in divided infringement cases,45 resulting in a 
small victory for the field of personalized medicine. 
This Comment argues that, despite the recent subject matter 
eligibility guidelines provided by the USPTO46 and in light of the 
infringement analysis framework set forth in Limelight III, only 
careful patent drafting with respect to what, specifically, is claimed 
and how multiple actors interact will ensure that claims directed to 
personalized medicine innovations are both eligible and protected. 
This Comment proceeds in four Parts. Part I discusses the history of 
personalized medicine and the current expectations for the field’s 
 
 39. Muniauction, Inc. v. Thomson Corp., 532 F.3d 1318, 1329 (Fed. Cir. 2008). 
 40. Akamai Techs., Inc. v. Limelight Networks, Inc., 692 F.3d 1301 (Fed. Cir. 2012) 
(en banc), rev’d 134 S. Ct. 2111 (2014) (Limelight I). 
 41. Limelight Networks, Inc. v. Akamai Techs., Inc., 134 S. Ct. 2111 (2014) (Limelight 
II). 
 42. Akamai Techs., Inc. v. Limelight Networks, Inc., 797 F.3d 1020 (Fed. Cir. 2015) 
(en banc) (Limelight III). 
 43. See infra Section III.B. 
 44. See generally Limelight Networks, 797 F.3d at 1020, 1022 (holding that when 
multiple actors perform the method steps, a single entity may be liable for direct 
infringement if the actions of others are attributable to the single entity, which occurs “(1) 
where that entity directs or controls others’ performance, and (2) where the actors form a 
joint enterprise”). 
 45. See id. at 1022–23. 
 46. See 2014 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. 
74618, 74618–33 (Dec. 16, 2014) (to be codified at 37 C.F.R. pt. 1); U.S. PATENT & 
TRADEMARK OFFICE, GUIDANCE FOR DETERMINING SUBJECT MATTER ELIGIBILITY 
OF CLAIMS RECITING OR INVOLVING LAWS OF NATURE, NATURAL PHENOMENA, & 
NATURAL PRODUCTS (Mar. 4, 2014) [hereinafter March 2014 Guidelines], https://www
.uspto.gov/patents/law/exam/myriad-mayo_guidance.pdf [https://perma.cc/6YTB-44ZL]; 
see also U.S. PATENT & TRADEMARK OFFICE, supra note 30, at 1–28. These publications 
provide instructions and examples for patent examiners to follow during the patent 
examination process.  
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implementation and development. Part II reviews patent law basics 
and discusses personalized medicine patents with respect to patent 
subject matter eligibility. Part III reviews patent infringement, the 
treatment of divided infringement in the Limelight line of cases, and 
discusses the framework for analyzing divided infringement cases 
presented in Limelight III. Part IV suggests how to effectively draft 
attainable and enforceable patents directed to personalized medicine 
methods. A brief conclusion follows. 
I.  PERSONALIZED MEDICINE 
Personalized medicine can generally be defined as “[t]he 
tailoring of medical treatment to the individual characteristics of each 
patient.”47 More specifically, personalized medicine is “[a] form of 
medicine that uses information about a person’s genes, proteins, and 
environment to prevent, diagnose, and treat disease.”48 Medical 
treatments should optimally benefit patients with minimal side effects 
and cost. Advancements in personalized medicine have already 
allow[ed] health care providers to: shift the emphasis in 
medicine from reaction to prevention[,] predict susceptibility to 
disease[,] improve disease detection, preempt disease 
progression[,]	.	.	.	avoid prescribing drugs with predictable side 
effects, reduce the time, cost, and failure rate of pharmaceutical 
clinical trials[, and] eliminate trial-and-error inefficacies that 
inflate health care costs	.	.	.	.49 
Unfortunately, most doctors currently only have the resources to 
make a decision about which treatment regimen to follow based on 
the patient’s symptoms, some basic test results, and the general 
efficacy of available treatment options.50 If Plan A fails to help or 
even harms the patient, the doctor will move on to Plan B, and then 
 
 47. U.S. FOOD & DRUG ADMIN., PAVING THE WAY FOR PERSONALIZED MEDICINE: 
FDA’S ROLE IN A NEW ERA OF MEDICAL PRODUCT DEVELOPMENT 7 (2013) (quoting 
the President’s Council of Advisors on Science and Technology). 
 48. NCI Dictionary of Cancer Terms, Personalized Medicine, NATIONAL CANCER 
INSTITUTE, https://www.cancer.gov/publications/dictionaries/cancer-terms/?CdrID=561717 
[https://perma.cc/J4NE-FFEU]; see also U.S. FOOD & DRUG ADMIN., supra note 47. 
 49. The Benefits of Personalized Medicine, JACKSON LABORATORY, https://www.jax
.org/genetics-and-healthcare/personalized-medicine/benefits-of-personalized-medicine [https://
perma.cc/PN7A-M2CL].  
 50. In 2012, it was estimated “that only 20 percent of practicing physicians had 
received any training on how to administer genomically guided medicine.” Turna Ray, 
Reality Check: Educating Physicians on Genomic Medicine, GENOMEWEB (Oct. 1, 2012), 
https://www.genomeweb.com/clinical-genomics/reality-check-educating-physicians-genomic
-medicine [https://perma.cc/LUS7-AACB].  
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Plan C if B fails. With advancements in the ability to tailor treatments 
based on a patient’s genome and to develop pharmaceuticals that are 
effective for people with specific genetic markers, practitioners can 
begin treatment by initially implementing said Plan C, potentially 
saving patients time, money, and adverse reactions to ineffective or 
dangerous treatments. 
Both the commissioner of the FDA and the director of the 
National Institutes of Health (the “NIH”) have recognized the 
importance of devoting funding to the research, testing, and 
application of personalized medicine techniques.51 The Precision 
Medicine Initiative, a White House research initiative, was allocated 
$215 million of the 2016 Presidential budget to further the 
development of personalized medicine.52 Tracing the development of 
personalized medicine will shed light on the promise of this emerging 
medical field. 
A. Personalized Medicine: Then and Now 
While modern personalized medicine focuses on tailoring 
treatment to best suit a patient’s genetic and molecular 
characteristics, its basic tenets can be traced back thousands of years. 
Around 400 BCE, Hippocrates stated, “It’s far more important to 
know what person the disease has than what disease the person 
has.”53 At that time, physicians examined a patient’s unique humor 
makeup—blood, phlegm, choler (yellow bile), and melancholia (black 
bile)—to best characterize a patient’s state of health prior to and 
during treatment.54 Physicians believed that ideally these four 
elements should be in perfect balance, which is known as eucrasia.55 
Under this theory, shifts away from this equilibrium, dyscrasia, 
resulted in disease.56 Physicians sought to cure a sick patient through 
a treatment regimen designed to equilibrate the particular humor 
imbalance, or by personalizing his care.57 
 
 51. Margaret A. Hamburg & Francis S. Collins, The Path to Personalized Medicine, 
363 NEW ENG. J. MED. 301, 301 (2010). 
 52. Fact Sheet: President Obama’s Precision Medicine Initiative, THE WHITE HOUSE 
(Jan. 30, 2015), https://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-
obama-s-precision-medicine-initiative [https://perma.cc/AL58-5YYJ]. 
 53. See, e.g., Edward Abrahams & Mike Silver, The History of Personalized Medicine, 
in INTEGRATIVE NEUROSCIENCE AND PERSONALIZED MEDICINE 3 (Evian Gordon & 
Stephen Koslow eds., 2010). 
 54. Id. at 4. 
 55. Id. 
 56. Id. 
 57. Id. 
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In 1957, Arno Motulsky58 “introduced the concept of tailoring 
medicine to an individual’s genetic makeup” in a paper entitled 
“Drug Reactions, Enzymes, and Biochemical Genetics,” effectively 
“launch[ing] a new field of research.”59 In his paper, Motulsky lists 
numerous studies correlating drug hypersensitivity or hyposensitivity 
with specific genetic traits of the patients.60 For example, one such 
study noted that some patients given the standard dose of an anti-
malarial drug, primaquine, developed hemolytic anemia.61 The red 
blood cells of these patients “lack[ed] sufficient enzymatic protection 
against damage by the drug” due to a genetic abnormality that caused 
defective glucose-6-phosphate dehydrogenase activity.62 Another 
study discussed by Motulsky highlighted genetically related sensitivity 
to a type of muscle relaxant due to reduced activity of the enzyme 
pseudocholinesterase and the subsequent insufficient inactivation of 
the drug.63 As more studies confirmed the link between genetic traits 
and responses to disease treatments, interest in the field grew among 
researchers and practitioners and advances in technology made such 
studies more feasible.64 
Some of the most significant advances in the field of genomics, 
and thus personalized medicine, have taken place during the past 
twenty-six years. The first occurred in 1990 with the approval of the 
three-billion-dollar Human Genome Project.65 By 2003, the 23,000 
genes making up the human genome had been sequenced and 
published online as a publicly available reference.66 Beginning in 
1999, research groups began to collaborate to identify upwards of ten 
million loci of variation within the human genome in an effort to link 
these changes with the “predispos[ition] to cancer, diabetes, 
Alzheimer’s disease, and cardiovascular and other diseases.”67 The 
 
 58. Arno Motulsky is the founder of pharmacogenetics and is a Professor of Genome 
Sciences at the University of Washington. See Arno Motulsky, U. OF WASH., http://www.gs
.washington.edu/faculty/motulsky.htm [https://perma.cc/R57U-AQNY]. 
 59. Abrahams & Silver, supra note 53, at 7 (analyzing Arno G. Motulsky, Drug 
Reactions, Enzymes, and Biochemical Genetics, 165 J. AM. MED. ASS’N 835 (1957)). 
 60. Arno G. Motulsky, Drug Reactions, Enzymes, and Biochemical Genetics, 165 J. 
AM. MED. ASS’N 835, 835–36 (1957). 
 61. Id. 
 62. Id. at 836. 
 63. Id. 
 64. Abrahams & Silver, supra note 53, at 7–8. 
 65. Id. 
 66. Id. at 8; see also GenBank Overview, GENBANK, http://www.ncbi.nlm.nih.gov
/genbank [https://perma.cc/9QXL-GZGN] (last updated Mar. 2016).  
 67. Abrahams & Silver, supra note 53, at 9; see also DBSNP, Short Genetic Variations, 
NAT’L CENTER FOR BIOTECHNOLOGY INFO., http://www.ncbi.nlm.nih.gov/SNP [https://
perma.cc/K4MN-XZNF]. 
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International HapMap Project followed in the early 2000s to begin 
sorting and collating the data into a format that would be more user-
friendly for researchers.68 Finally, within the last decade or so, 
massive research studies called genome-wide association studies 
(“GWAS”) have commenced in an effort to identify genetic patterns 
in people with specific diseases.69 
Since 2006, the federal government has been searching for ways 
to improve the “regulatory, industrial, and social	.	.	.	support” for 
personalized medicine initiatives in what has become “a priority issue 
at the highest levels of government.”70 In 2010, FDA Commissioner, 
Margaret Hamburg, and NIH Director, Francis Collins, recognized 
that such groundbreaking progress had limitless potential for 
improving patient-specific, targeted therapies.71 They announced 
support for a “national highway system for personalized medicine” to 
help “accelerate the translation of research into medical products and 
therapies.”72 In a 2013 FDA report, Hamburg affirmed “the Agency’s 
ongoing commitment to this important and emerging area of 
medicine.”73 The report begins by discussing one of the poster 
children for personalized medicine, the cystic fibrosis drug Kalydeco, 
which was designed to treat abnormal protein function resulting from 
a specific gene mutation seen in four percent of cystic fibrosis 
patients.74 Expectations have remained high, as the federal 
government has continued to allocate significant resources to the field 
of personalized medicine as recently as 2016.75 
However, despite all the grand discoveries, optimistic 
announcements, and devotion of resources to various initiatives, a 
closer look at the developing landscape of patent law indicates that 
patenting innovations in this promising field has become much more 
difficult. These changes could have lasting and disastrous effects on 
the development of personalized medicine. 
 
 68. Abrahams & Silver, supra note 53, at 9. 
 69. Id. 
 70. Id. at 12. 
 71. Hamburg & Collins, supra note 51, at 301. 
 72. Id. at 304. 
 73. U.S. FOOD & DRUG ADMIN., supra note 47, at 2. 
 74. Id. at 3. 
 75. See Fact Sheet: President Obama’s Precision Medicine Initiative, supra note 52 
(allocating $215 million of the 2016 Presidential budget to the Precision Medicine 
Initiative). 
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II.  SUBJECT MATTER ELIGIBILITY 
Changes in what is fundamentally considered “patentable” by 
the USPTO have left many wondering whether biotechnology-
directed patents will receive protection in the near future.76 This Part 
analyzes key cases in the development of current eligible subject 
matter, focusing on the lasting effects on the ability to patent future 
personalized medicine methods. 
A. Patentable Matter, Pre-2012 
Title 35, Section 101 of the United States Code states that 
“[w]hoever invents or discovers any new and useful process, machine, 
manufacture, or composition of matter, or any new and useful 
improvement thereof, may obtain a patent therefor.”77 However, 
judicial exceptions to patent eligible subject matter include laws of 
nature, physical phenomena, and abstract ideas.78 In 1980, the 
Supreme Court visited what subject matter was considered statutorily 
eligible for a patent under 35 U.S.C. §	101 in Diamond v. 
Chakrabarty.79  
At issue in Chakrabarty was whether a bacterium given the 
ability to break down crude oil through genetic engineering was 
eligible for patent protection.80 In its decision, the Court noted that 
“[i]n choosing such expansive terms as ‘manufacture’ and 
‘composition of matter,’ modified by the comprehensive ‘any,’ 
Congress plainly contemplated that the patent laws would be given 
wide scope.”81 As the “[r]espondent’s micro-organism constitute[ed] a 
‘manufacture’ or ‘composition of matter’ within” §	101, being a 
“product of human ingenuity[,]” the bacterium was indeed eligible for 
patent protection.82 Additionally, the Court dismissed arguments that 
living things were not patentable83 and that protection of 
 
 76. See Joanna Brougher & Konstantin M. Linnik, Patents or Patients: Who Loses?, 32 
NATURE BIOTECHNOLOGY 877, 877–79 (2014) (discussing “[h]igher hurdles to obtaining 
a patent”); Gene Quinn, The Looming Patent Nightmare Facing the Pharmaceutical 
Industry, IP WATCHDOG (July 18, 2015), http://www.ipwatchdog.com/2015/07/08/the-
looming-patent-nightmare-facing-the-pharmaceutical-industry/id=51428 [https://perma.cc
/5ZEY-Y8G8] (lamenting that a “Supreme Court that obviously doesn’t know the first 
thing about technology is about to upend America’s high tech economy”).  
 77. 35 U.S.C. §	101 (2012). 
 78. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 
 79. 447 U.S. 303 (1980). 
 80. Id. at 305–06. 
 81. Id. at 308. 
 82. Id. at 304. 
 83. Id. at 315 (stating that the relevant distinction is “between products of nature, 
whether living or not, and human-made inventions”). 
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microorganisms requires express authorization from Congress.84 In 
sum, the Court at this point interpreted §	101 to be a broad filter with 
respect to patent eligible subject matter in the absence of a judicial 
exception. 
Even as recently as 2011, the Federal Circuit still referred to the 
“coarse eligibility filter” of §	101 with respect to the eligibility of 
method patents directed to evaluating and improving the safety of 
immunization schedules.85 In Classen Immunotherapies v. Biogen 
IDEC,86 one of the claims in question was directed to “[a] method of 
immunizing a mammalian subject while reducing the risk of said 
subject thereby developing at least one chronic immune-mediated 
disorder, which comprises: (I) screening a plurality of immunization 
schedules	.	.	.	and (II) immunizing said subject according to a subject 
immunization schedule	.	.	.	associated with a lower risk of [disorder] 
development.87 Petitioners claimed that the “screening” process 
mentioned in the patent was a mental process, and thus the claims 
were not patent eligible because they were directed to an abstract 
idea.88 However, when the court considered the invention as a whole, 
it noted that Step II was directed at an actual immunization, which 
was enough for the claim to not be considered directed to an abstract 
idea.89 Thus, because personalized medicine patents are directed to 
screening and subsequent treatment, it is likely that these patents 
would have readily survived the requirements of §	101 as interpreted 
at this point in time. 
B. Refining the “Coarse Filter,” 2012–Present 
Two important Supreme Court cases have drastically changed 
the outlook for biotechnology and medical patents, specifically those 
directed to personalized treatment methods: Mayo Collaborative 
Services v. Prometheus Labs90 and Association for Molecular 
Pathology v. Myriad Genetics.91 These cases illuminate the specific 
 
 84. Id. (noting that “Congress has performed its constitutional role in defining 
patentable subject matter	.	.	.	[and] we perform ours in construing the language Congress 
has employed”). 
 85. Classen Immunotherapies v. Biogen IDEC, 659 F.3d 1057, 1066 (Fed. Cir. 2011) 
(stating that “the statutory role of §	101 [is] as a ‘coarse eligibility filter,’ not [as] the final 
arbiter of patentability”).  
 86. 659 F.3d 1057 (Fed. Cir. 2011). 
 87. U.S. Patent No. 6,420,139 (filed July 16, 2002).  
 88. See Classen, 659 F.3d at 1062–63. 
 89. Id. at 1068. 
 90. 132 S. Ct. 1289 (2012). 
 91. 133 S. Ct. 2107 (2013). 
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repercussions that narrowing the previously coarse §	101 filter has had 
on life-saving innovation. 
1.  Mayo and Something More 
At issue in Mayo was whether the patent claims contained 
“something more” than a natural law, making them patent eligible.92 
In Mayo, the claims in question were directed to a method of 
calibrating drug dosage based on the concentration of drug 
metabolites present in a patient’s blood.93 Specifically, the claim 
called for the administration of a thiopurine drug to a patient, 
determination of the level of a specific metabolite, 6-thioguanine, in 
the patient’s blood, and subsequent alteration of drug dosage based 
on the test results.94 Invalidating the claim as non-patentable subject 
matter, the Court held that attempting to transform an unpatentable 
law of nature—blood metabolite concentration—into patent eligible 
subject matter requires “more than simply stat[ing] the law of nature 
while adding the words ‘apply it.’	”95 Thus, the inquiry into a patent 
centered around a law of nature became whether “the patent claims 
add enough to their statements of the correlations to allow the 
processes they describe to qualify as patent-eligible processes that 
apply natural laws.”96 
Biotech patent drafters reacted negatively to the decision. Some 
interpreted the opinion to shift the burden to the patent drafter to 
ensure claims have enough additional features to confirm they are an 
application of a law of nature, not simply a claim to it.97 Others felt 
Mayo could be interpreted as invalidating patents on diagnostic 
methods, as those methods are usually directed to laws of nature.98 
More dramatically, the founder of the blog IPWatchdog.com stated 
that “[t]hose in biotech, medical diagnostics and pharmaceutical 
industries have just been taken out behind the woodshed and 
 
 92. See Mayo, 132 S. Ct. at 1297 (deciding “whether the claims do significantly more 
than simply describe these natural relations”). 
 93. Id. at 1290. 
 94. Id. at 1295. 
 95. Id. at 1294. 
 96. Id. at 1297. 
 97. Dennis Crouch, Mayo v. Prometheus: Natural Process + Known Elements = 
Normally No Patent, PATENTLYO (Mar. 20, 2012), http://patentlyo.com/patent/2012/03/mayo-v-
prometheus-natural-process-known-elements-normally-no-patent.html [https://perma.cc/E5GY
-PA6A]. 
 98. See Rebecca S. Eisenberg, Diagnostics Need Not Apply, 21 B.U. J. SCI. & TECH. L. 
256, 266–68 (2015) (exemplifying how the Court’s analysis in Mayo places the 
fundamentals of diagnostics in the “realm of natural laws,” and thus makes them 
unpatentable). 
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summarily executed by the Supreme Court this morning[,]” as the 
decision could be interpreted to imply that even an application of a 
law of nature was no longer patent eligible.99 Overall, the Mayo 
decision resulted in a great deal of confusion, as the Court failed to 
explain what exactly would be “enough” to move something beyond a 
mere statement of a law of nature.100 
2.  Myriad and Splitting Strands 
In Myriad, the Supreme Court specifically addressed how much 
“more” a patent claim directed to a product of nature, specifically 
DNA, was required to include to be patent eligible;101 this was 
significant, as historically, a substance isolated from nature was patent 
eligible.102 Two different claims were at issue in Myriad: one directed 
to an isolated DNA sequence associated with a specific gene,103 and 
one directed to the stable, lab-generated cDNA of the same gene.104 
The Court came to the conclusion that, unlike the bacterium in 
Chakrabarty,105 the subject of Myriad Genetics’s patent was simply an 
excised gene that previously existed in nature.106 Additionally, the 
Court noted that “[l]aws of nature	.	.	.	‘are the basic tools of scientific 
and technological work,’	” and “[p]atent protection strikes a delicate 
balance between” incentivization and impeding innovation.107 With 
respect to the second claim, the Court quickly concluded that a “lab 
technician unquestionably creates something new when cDNA is 
made	.	.	.	. As a result,	.	.	.	[cDNA] is patent eligible under §	101.”108 
 
 99. Gene Quinn, Killing Industry: The Supreme Court Blows Mayo v. Prometheus, IP 
WATCHDOG (Mar. 20, 2012), http://www.ipwatchdog.com/2012/03/20/supreme-court-mayo
-v-prometheus/id=22920/ [https://perma.cc/6MHW-FAG2 (staff-uploaded archive)]. 
 100. See Mayo, 132 S. Ct. at 1297; Bernard Chao, Moderating Mayo, 107 NW. U. L. 
REV. 423, 424–25 (2012). 
 101. See Ass’n for Molecular Pathology v. Myriad Genetics, 133 S. Ct. 2107, 2116 
(2013) (deciding “whether Myriad’s patents claim any ‘new and useful	.	.	.	composition of 
matter,’	.	.	.	or instead claim naturally occurring phenomena”). 
 102. See, e.g., Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 
1911) (holding that “mak[ing adrenaline] available for any use by removing it from the 
other gland-tissue in which it was found, and, while it is of course possible logically to call 
this a purification of the [adrenaline], it became for every practical purpose a new 
thing	.	.	.”), aff’d in part, rev’d in part, 196 F. 496 (2d Cir. 1911). 
 103. See Myriad Genetics, 133 S.Ct. at 2113 (giving the example of a claim “assert[ing] 
a patent on ‘[a]n isolated DNA coding for a BRCA1 polypeptide’	”). 
 104. See id. (indicating claim two of the U.S. Patent No. 5,747,282 is for “the sequence 
of cDNA that codes for the BRCA1 amino acids listed in claim 1”). 
 105. See supra Section II.A (discussing the Court’s decision in Chakrabarty). 
 106. See Myriad Genetics, 133 S. Ct. at 2117–18. 
 107. See id. at 2116. 
 108. See id. at 2119. 
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While some anticipated the result in Myriad, the Court’s holding 
has still changed the tenet that naturally occurring substances were 
patent-eligible if isolated from nature.109 Specifically, Myriad 
foreclosed the possibility of obtaining patents on human genes.110 
Under a broader interpretation, Myriad effectively rendered 
naturally-occurring biomarkers patent ineligible.111 It is important to 
note, however, that “[m]ethod claims generally play a much more 
important role than isolated DNA claims in the patenting of 
innovations in [diagnostics and personalized medicine,]”112 as the 
patents are generally directed to the personalized diagnostic and 
treatment process.113 Yet, even if Myriad did not cripple the field of 
personalized medicine, the lack of guidance as to subject matter 
eligibility required clarification from the USPTO to aid in both the 
drafting and prosecution of biotech patents. 
3.  The Aftermath 
Following the Myriad and Mayo decisions, the USPTO, in March 
2014, released a procedure for determining subject matter eligibility 
for all things natural.114 The guidelines set forth a three-question 
framework for determining if a claim passes the §	101 threshold: 
 Step 1: Is the claim to a process, machine, manufacture, or 
composition of matter? If yes, move to Step 2A; if no, 
claim is not subject matter eligible. 
 Step 2A: Does the claim recite or involve a law of nature, 
natural phenomenon, or abstract idea? If no, claim is 
subject matter eligible under §	101; if yes, proceed to Step 
2B. 
 Step 2B: Does the claim recite additional elements that 
amount to significantly more than the judicial exception? If 
 
 109. See Parke-Davis & Co. v. H. K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911). 
 110. See, e.g., Courtenay C. Brinckerhoff, Supreme Court Decides Myriad Gene Patents 
Case, Holds Isolated Human Genes May Not Be Patented, PHARMAPATENTS (June 13, 
2013), https://www.pharmapatentsblog.com/2013/06/13/supreme-court-decides-myriad-gene-
patents-case/ [https://perma.cc/KD93-FDN9].  
 111. See Eisenberg, supra note 98, at 277. 
 112. Christopher M. Holman, Mayo, Myriad, and the Future of Molecular Diagnostics 
and Personalized Medicine, 15 N.C. J.L. & TECH. 639, 639 (2014). 
 113. Christopher M. Holman, Patent Eligibility as a Policy Lever to Regulate the 
Patenting of Personalized Medicine, in PERSPECTIVES ON PATENTABLE SUBJECT 
MATTER 114, 117 (Michael B. Abramowicz et al. eds., 2015). 
 114. See March 2014 Guidelines, supra note 46, at 1–10. 
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yes, claim qualifies as eligible subject matter under §	101; if 
no, claim is not subject matter eligible.115 
Furthermore, the USPTO clarified how to determine whether a 
claim has elements that amount to “significantly more” than the 
judicial exception by setting forth a non-exhaustive list of various 
factors.116 Limitations which can weigh in favor of “significantly 
more” include the following: methods limiting the scope of a claim 
from encompassing a judicial exception; additional steps that are not 
added essentially for show; steps in addition to the judicial exception 
that go beyond saying “apply it”; and steps that go beyond 
conventional techniques in a particular field.117 
However, in the examples that apply this test, the USPTO said 
that if gunpowder had been invented today, it would not be eligible 
for patent protection because it involves a mixture of natural products 
without “something significantly different.”118 Following an outcry 
from the chemistry and life sciences patent community, the USPTO 
opted to revise their test language from “reciting or involving” a 
judicial exception, which all life sciences patents do, to asking if the 
claims are “directed to” a judicial exception, and, if so, whether they 
contain “something more.”119 Additional guidance regarding life 
science patent claims continues to confuse, rather than clarify, the 
issue.120 
Unfortunately, the Supreme Court’s precedent and the USPTO’s 
subject matter eligibility guidelines have already failed to protect 
more than one life-changing discovery. For example, in 2015, a 
researcher reported discovering a bacterium that, when cultured, 
produced compounds that killed “a wide variety of pathogens without 
detectible resistance.”121 In a Office action, the patent application’s 
 
 115. Id. at 2 (paraphrasing steps for determining subject matter eligibility). 
 116. See id. at 3. 
 117. Id. at 3–5. 
 118. See id. at 9–10. 
 119. See, e.g., Jonathan Singer & Rebecca Shult, USPTO Guidance on Natural Product 
Development, PHARMACEUTICAL COMPLIANCE MONITOR (Dec. 5, 2014), http://www
.pharmacompliancemonitor.com/uspto-guidance-natural-product-development/8057/ [https://
perma.cc/H2XW-UB58]. 
 120. See generally U.S. PATENT & TRADEMARK OFFICE, supra note 30 (discussing 
several examples of life sciences patents claims while also cautioning that these examples 
are not to be considered too closely since eligibility is analyzed on a case-by-case basis). 
 121. Warren D. Woessner, “Isolated” Natural Products Still in Purgatory Post-PTO 
Guidance?, PATENTS4LIFE (Apr. 2015), http://www.patents4life.com/2015/04/isolated-
natural-products-still-in-purgatory-post-pto-guidance/ [https://perma.cc/4TXH-YQ5A]. 
See generally Losee L. Ling et al., A New Antibiotic Kills Pathogens Without Detectable 
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examiner deemed the isolated antibiotic patent ineligible under the 
§	101 statutory bar because it failed to “includ[e] any elements in 
addition to the natural product.”122 To fully understand the 
implications of such a ruling by the USPTO, it is worth noting that 
“[n]early 80% of our current antibiotics were originally derived from 
natural sources.”123 Surely the USPTO did not intend to exclude 
novel, broad-spectrum antibiotics from patent protection. However, 
until the USPTO further clarifies the §	101 eligibility analysis,124 
patentees will likely need to claim “non-natural” forms of isolated 
natural products, such as a synthetic variant of said natural product, in 
order to maintain patent eligibility.125 
While there is little case law following the USPTO’s latest 
subject matter eligibility guidelines, the Federal Circuit indicated its 
discomfort with the current standards in Ariosa Diagnostics, Inc. v. 
Sequenom, Inc.126 and its subsequent en banc rehearing denial.127 
The patent in Ariosa Diagnostics claimed a method for detecting 
cell-free fetal DNA (“cffDNA”) in a mother’s blood that could then 
be used for non-invasive genetic testing of a fetus.128 Despite 
Sequenom’s argument that the method was a narrow and specific 
patent eligible application involving a newly discovered natural 
 
Resistance, 517 NATURE BIOTECHNOLOGY 455 (2015) (describing the research that 
produced the bacterium that “kills pathogens without detectable resistance”).  
 122. Non-Final Rejection, U.S. Patent Application Serial No. 14/095,415, at 2 (filed 
Dec. 3, 2013) http://portal.uspto.gov/pair/PublicPair [https://perma.cc/SA6A-8SCR]. 
 123. Teresa Griffiths & Helen Bellchambers, Breakthough Antibiotic Not Patentable in 
the US, LEXOLOGY (Feb. 11, 2015), http://www.lexology.com/library/detail.aspx?g
=9e39370a-57d5-4cfc-b223-07ce0cd0519d [https://perma.cc/377C-7FHU]. 
 124. The issuance of the updated December 2014 Guidelines revising the language of 
the test indicates that the USPTO is willing to continue clarifying its test to stay consistent 
with Supreme Court rulings. See 2014 Interim Guidance on Patent Subject Matter 
Eligibility, 79 Fed. Reg. 74618, 74618–33 (Dec. 16, 2014) (to be codified at 37 C.F.R. pt. 1). 
 125. See generally Woessner, supra note 121 (discussing the patent eligibility of 
naturally and non-naturally occurring crystalline forms of products isolated from nature). 
 126. 788 F.3d 1371 (Fed. Cir. 2015), reh’g denied, 809 F.3d 1282 (Fed. Cir. 2015) (en 
banc). 
 127. Ariosa Diagnostics, Inc. v. Sequenom, Inc., 809 F.3d 1282 (Fed. Cir. 2015). 
 128. Ariosa Diagnostics, Inc., 788 F.3d at 1373. The patent claim was directed to  
[a] method for detecting a paternally inherited nucleic acid of fetal origin 
performed on a maternal serum or plasma sample from a pregnant female, which 
method comprises amplifying a paternally inherited nucleic acid from the serum or 
plasma sample and detecting the presence of a paternally inherited nucleic acid of 
fetal origin in the sample.  
Id. at 1373–74. 
95 N.C. L. REV. 493 (2017) 
510 NORTH CAROLINA LAW REVIEW [Vol. 95 
phenomenon, cffDNA, the Ariosa court held that the claim was 
directed to patent ineligible subject matter.129 
However, in his concurrence, Judge Linn stated that he “join[ed] 
the court’s opinion invalidating the claims	.	.	.	only because [he was] 
bound by the sweeping language of the test set out in Mayo.”130 He 
found that Sequenom’s patent was distinguishable from the case in 
Mayo, as the claims were directed to non-conventional activities 
(non-invasive fetal DNA testing) while the patent at issue in Mayo 
was directed to routine testing of blood metabolite concentrations.131 
During the en banc rehearing, Judges Lourie and Moore expanded on 
Judge Linn’s concurrence stating that “the claims here are directed to 
an actual use of the natural material of cffDNA	.	.	.	[b]ut applying 
Mayo, we are unfortunately obliged to divorce the additional steps 
from the asserted natural phenomenon to arrive at a conclusion that 
they add nothing innovative to the process.”132 Thus, while these 
rumblings in the Federal Circuit are promising, personalized medicine 
patents directed to natural laws and phenomena will still require 
methods claims directed to non-conventional “something more” 
steps. 
As discussed in Part IV, these guidelines can be implemented to 
carefully draft a narrow personalized medicine patent. However, 
drafting a patent requires preemptively addressing the above-
mentioned questions posed by the USPTO. One of the most effective 
ways to do so involves adding the aforementioned method steps.133 
However, in doing so the drafter will need to take precautions to 
ensure the patent holder can protect her rights should another party 
infringe. The additional “something more” application steps, which 
the USPTO currently requires, result in personalized medicine 
patents having attributes that, until recently, made successful 
infringement suits exceedingly difficult.134 
III.  THE DIVIDED INFRINGEMENT LOOPHOLE 
Typically, a patentee can have a cause of action against both 
direct and indirect infringers under 35 U.S.C §	271.135 Direct 
infringement occurs when a party “without authority, makes, uses, 
 
 129. See id. at 1378–79. 
 130. Id. at 1380 (Linn, J., concurring). 
 131. See id. at 1380–81. 
 132. Ariosa Diagnostics, Inc., 809 F.3d at 1286. 
 133. See March 2014 Guidelines, supra note 46, at 4.  
 134. See infra Section IV.B.2.  
 135. 35 U.S.C. §	271(a)–(d) (2012). 
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offers to sell, or sells any patented invention, within the United 
States.”136 For methods patents, “a party [must] perform or use each 
and every step or element of a claimed method” to constitute direct 
infringement.137 Additionally, one can be liable for indirect 
infringement by either inducing or contributing to infringement.138 A 
party induces infringement if he “actively induces infringement of a 
patent.”139 
However, plaintiffs may not have a cause of action when 
different parties carry out the steps of a method patent. Divided 
infringement, sometimes called joint infringement, of method patents 
occurs when multiple parties perform each and every step of a 
claimed process.140 However, according to the single entity rule, in 
situations “where the actions of multiple parties combine to perform 
every step of a claimed method, the claim is directly infringed only if 
one party exercises ‘control or direction’ over the entire process such 
that every step is attributable to the controlling party, i.e., the 
‘mastermind.’	”141 Additionally, “indirect infringement, whether 
inducement to infringe or contributory infringement, can only arise in 
the presence of direct infringement.”142 Thus, as the Federal Circuit 
noted in BMC Resources, Inc. v. Paymentech, L.P.,143 a loophole 
exists wherein “the standard requiring control or discretion for a 
finding of joint infringement may in some circumstances allow parties 
to enter into arms-length agreements to avoid infringement	.	.	.	[, but] 
this concern does not outweigh concerns over expanding the rules 
governing direct infringement.”144 This Part examines the Federal 
Circuit’s attempts to close the divided infringement loophole, and 
how the resulting guidelines presented in Limelight III will favorably 
impact the protection of personalized medicine patents necessarily 
directed to multiple actors. 
 
 136. Id. §	271(a). 
 137. BMC Res., Inc. v. Paymentech, L.P., 498 F.3d 1373, 1378 (Fed. Cir. 2007). 
 138. Mark A. Lemley et al., Divided Infringement Claims, 33 AIPLA Q. J. 255, 257 
(2005). 
 139. 35 U.S.C. §	271(b) (2012). 
 140. See Akami Techs., Inc. v. Limelight Networks, Inc., 692 F.3d 1301, 1305–06 (Fed. 
Cir. 2012) (en banc) (noting that “[t]he problem of divided infringement in induced 
infringement cases typically only arises with respect to method patents”), rev’d, 134 S. Ct. 
2111 (2014). 
 141. Muniauction, Inc. v. Thomson Corp., 532 F.3d 1318, 1329 (Fed. Cir. 2008) 
(quoting BMC Res., 498 F.3d at 1380–81). 
 142. Dynacore Holdings Corp. v. U.S. Philips Corp., 363 F.3d 1263, 1272 (Fed. Cir. 
2004). 
 143. BMC Res., Inc. v. Paymentech, L.P., 498 F.3d 1373 (Fed. Cir. 2007). 
 144. Id. at 1381. 
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A. An Attempt to Overrule BMC Resources and Muniauction 
In Limelight I,145 Akamai Technologies held a patent that 
claimed a method for creating an “infrastructure designed to serve 
Web content efficiently, effectively, and reliably to end users.”146 In 
this method, a content provider can tag content supported on a set of 
hosting servers, which will then be served, in embedded form, from 
the content provider’s site.147 Limelight, the alleged infringer, was 
executing the patented method, except instead of using the content 
provider, Limelight tagged external content for service, and its 
customers received instructions on how to tag the content 
themselves.148 Thus, Limelight itself was not actually practicing each 
and every step of the allegedly infringed patent. Consistent with the 
single entity rule set forth in BMC Resources, the district court issued 
Limelight a judgment as a matter of law.149 Akamai appealed the 
Federal Circuit and again “address[ed] the question [of] whether a 
defendant may be held liable for induced infringement if the 
defendant has performed some of the steps of a claimed method and 
has induced other parties to commit the remaining steps.”150 
In revisiting the court’s holding in BMC Resources, affirmed in 
Muniauction, Inc. v. Thomson Corp.,151 the Limelight I court noted 
that the decisions in those cases resulted from “the propositions that 
(1) liability for induced infringement requires proof of direct 
infringement and (2) liability for direct infringement requires that a 
single party commit all the acts necessary to constitute 
infringement.”152 The Federal Circuit then decided it should find a 
way to ensure that those who induce infringement are held liable even 
when the acts of infringement are committed by multiple parties, 
resulting in no direct infringement.153 In its conclusion, the Federal 
Circuit held that although “Akamai [was not] entitled to prevail on its 
theory of direct infringement, the evidence could support a judgment 
 
 145. Akami Techs., Inc. v. Limelight Networks, Inc., 692 F.3d 1301 (Fed. Cir. 2012) (en 
banc), rev’d, 134 S. Ct. 2111 (2014).  
 146. Id. at 1306; U.S. Patent No. 6,108,703 (filed May 19, 1999). 
 147. ‘703 Patent. 
 148. See Limelight Networks, Inc., 692 F.3d at 1306.  
 149. Id. at 1307; see also BMC Res., Inc., 498 F.3d at 1375, 1380. 
 150. Limelight Networks, Inc., 692 F.3d at 1305. 
 151. Muniauction, Inc. v. Thomson Corp., 532 F.3d 1318, 1329 (Fed. Cir. 2008). 
 152. Limelight Networks, Inc., 692 F.3d at 1308. 
 153. Id. at 1308–09 (“If a party has knowingly induced others to commit the acts 
necessary to infringe the plaintiff’s patent and those others commit those acts, there is no 
reason to immunize the inducer from liability for indirect infringement simply because the 
parties have structured their conduct so that no single defendant has committed all the 
acts necessary to give rise to liability for direct infringement.”). 
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in its favor on a theory of induced infringement,”154 which effectively 
ignored the established precedent requiring there be a case of direct 
infringement before a cause of action for indirect infringement 
exists.155 The decision closed a frustrating loophole in patent law and 
was met with cautious optimism.156 However, at least one scholar 
predicted that the Supreme Court would grant certiorari and hear an 
appeal of such a radical decision.157 
After granting certorari, the Supreme Court unanimously and 
succinctly held that “liability for infringement must be predicated on 
direct infringement.”158 Before remanding the case to the Federal 
Circuit to properly apply §	271(b) and potentially revisit the 
appropriateness of the application of the single entity rule under 
§	271(a),159 the Court stated that “[a] desire to avoid Muniauction’s 
natural consequences does not justify fundamentally altering the rules 
of inducement liability.”160 
Unlike the 2012 Federal Circuit decision, the Supreme Court 
reversal was met with concern because of the broad interdisciplinary 
implications.161 With respect to personalized medicine, it was noted 
that “[a]s personalized medicines often consist of screening a patient 
for a biomarker and then administering a therapy based on the 
results, if the two steps are performed by two independent entities, 
infringement liability can thus be avoided.”162 Thankfully, the Federal 
 
 154. Id. at 1319. 
 155. See id. at 1319–20 (Newman, J., dissenting) (noting that in BMC Resources and 
Muniauction, the court applied the single entity rule and “held there can be no liability for 
infringement, although all of the claim steps are performed” when there is not a “single 
mastermind”). 
 156. See, e.g., Dennis Crouch, Joint Infringement: Federal Circuit Changes the Law of 
Inducement, PATENTLYO (Aug. 31, 2012), http://patentlyo.com/patent/2012/08/joint-
infringement-federal-circuit-changes-the-law-of-inducement.html [https://perma.cc/SM6V-
74NY]. 
 157. See, e.g., “Joint” Infringement and the Federal Circuit’s Akamai and McKesson En 
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Circuit took the Supreme Court’s veiled suggestion that it should 
revisit §	271(a) upon remand. 
B. Divided Infringement Revisited 
In 2015, after rehearing Akamai v. Limelight on remand, the 
Federal Circuit updated and clarified the framework for determining 
divided infringement under 35 U.S.C. §	271(a) in Limelight III.163 
First, a single entity must be responsible for the performance of all 
the steps of a claimed method for a valid infringement claim, thus 
satisfying the direct infringement requirement.164 Second, if more than 
one entity is involved, the “court must determine whether the acts of 
one are attributable to the other such that a single entity is 
responsible for the infringement.”165 Third, there are two situations in 
which one party can be held responsible for another’s performance of 
steps in a method patent: “(1) where that entity directs or controls 
others’ performance, and (2) where the actors form a joint 
enterprise.”166 Direction or control can be evidenced by agency 
relationships and the existence of contracts, similar to vicarious 
liability in tort law.167 
The addition of a “joint enterprise” category effectively 
expanded the circumstances under which a party can be liable for 
direct infringement under §	271(a).168 Here, if “two or more actors 
form a joint enterprise, all can be charged with the acts of the other, 
rendering each liable for the steps performed by the other as if each is 
a single actor.”169 The Federal Circuit held that 
[a] joint enterprise requires proof of four elements: (1) an 
agreement, express or implied, among the members of the 
group; (2) a common purpose to be carried out by the group; 
(3) a community of pecuniary interest in that purpose, among 
 
 163. See Akami Techs., Inc.v. Limelight Networks, Inc., 797 F.3d 1020, 1022–23 (Fed. 
Cir. 2015) (en banc). 
 164. Id. at 1022. 
 165. Id. 
 166. Id. 
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Resources. See BMC Resources, Inc. v. Paymentech, L.P., 498 F.3d 1373, 1380–81 (Fed. 
Cir. 2007) (describing the single-entity rule). 
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the members; and (4) an equal right to a voice in the direction 
of the enterprise, which gives an equal right of control.170 
Furthermore, the question of whether there is a single entity in charge 
of the infringing actions or a joint enterprise among multiple actors is 
a question of fact for a jury.171 
The framework presented in Limelight III to evaluate the 
existence of a joint enterprise has already been applied—albeit in a 
non-binding district court—in an infringement suit brought to defend 
a patent directed to a treatment regimen172 associated with reducing 
the toxicity of a specific mesothelioma therapeutic in Eli Lilly and Co. 
v. Teva Parenteral Medicines, Inc.173 The patent at issue, No. 7,772,209 
(the “	‘209 patent”), was directed to 
an improved method for administering pemetrexed disodium 
[to a patient in need of chemotherapeutic treatment] 
comprising “a) administration of between 3500 µ and about 
1000 µ of folic acid prior to the first administration of 
pemetrexed disodium; b) administration of about 500 µ to 
about 1500 µ of vitamin B12, prior to the first administration of 
pemetrexed disodium; and c) administration of pemetrexed 
disodium.”174 
In this case, defendant Teva, makers of a generic version of plaintiff 
Eli Lilly’s drug, were distributing instructions to physicians to follow 
the treatment regimen described in the above claim of Eli Lilly’s ‘209 
patent.175 The evidence presented included packaging information 
passed from the doctor to the patient that clearly stated that “it is 
very important to take folic acid during your treatment with 
ALITMA [the drug in question] to lower your chances of harmful 
side effects.”176 Thus, because the physicians administered the B12 
injections and the drug itself, while the patients were responsible for 
taking the folic acid, the question arose as to whether all the steps of 
the claimed method could be attributable to the defendant, allowing 
Eli Lilly to bring a direct infringement claim under §	271(a) and an 
induced or contributory infringement claim under §	271(b).177 The Eli 
Lilly court found that “[t]he evidence showed that physicians specify 
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both the ‘manner and timing’ [of folic acid administration] in detail,” 
and that was enough to conclude that the performance of all of the 
steps of the ‘209 patent could be attributed to a single actor.178 
While this case is only a single example of a company being able 
to protect a method patent requiring performance of multiple actors, 
it is still promising and informative. First, it shows that it is not 
impossible to win an infringement suit when a patent is directed at 
multiple actors. Second, it provides some guidance with respect to 
counseling clients during and after the drafting process to ensure they 
act in a way that a jury could find, at minimum, the existence of a 
joint enterprise when the method is implemented. Finally, Eli Lilly 
sets a promising, though non-binding, example for future divided 
infringement cases involving patents directed to personalized 
medicine methods, especially in combination with navigating subject 
matter eligibility. 
IV.  DRAFTING PERSONALIZED MEDICINE PATENTS 
The following Part first discusses personalized method patents. 
Then, this Part suggests some patent drafting and implementation 
techniques for optimizing personalized medicine directed patents in 
light of Mayo, Myriad, and Limelight III. As discussed above, 
following the Supreme Court’s decision in Limelight II to uphold the 
divided infringement loophole,179 the general consensus was that 
personalized medicine would quickly become a thing of the past, 
despite multiple government initiatives to advance personalized 
medicine.180 Thankfully, the Federal Circuit recently relaxed the 
definition of what constitutes a single party being in control of a third 
party and provided a framework from which one can draft 
protectable, directly infringeable patents.181 
A. Personalized Medicine Patents in General 
Typically, “useful processes” are patent eligible.182 While this 
framework is “subject to the conditions and requirements of” 35 
U.S.C. §	101183 and other patent statutes,184 it is important for the 
purpose of this Comment to note that a “useful process” is defined as 
 
 178. Id. at 1043. 
 179. See supra Section III.A. 
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a “process, art or method, and includes a new use of a known process, 
machine, manufacture, composition of matter, or material.”185 A 
useful process could include: (1) identification of a genetic or 
biochemical marker through diagnostic testing and (2) the direction 
of treatment based upon the significance of that marker.186 These two 
steps form the core of a personalized medicine patent.187 
Take, for example, the following patent claim deemed subject 
matter eligible by the Federal Circuit in Classen Immunotherapies v. 
Biogen IDEC: 
A method of immunizing a mammalian subject which 
comprises: 
(I) screening a plurality of immunization schedules, by 
(a) identifying a first group of mammals and at least a 
second group of mammals,	.	.	.	the first group of mammals 
having been immunized with one or more [vaccine] 
doses	.	.	.	according to a first screened immunization 
schedule, and the second group of mammals having been 
immunized with one or more [vaccine]	.	.	.	according to a 
second screened immunization schedule	.	.	. 
(b) comparing the effectiveness of said first and second 
screened immunization schedules in protecting against or 
inducing a chronic immune-mediated disorder in said first 
and second groups [and]	.	.	. 
(II) immunizing [a] subject according to a subject immunization 
schedule,	.	.	.	in accordance with said lower risk screened 
immunization schedule	.	.	.	.188 
In this claim, the “identification” step takes place when the 
immunization schedule is screened to determine which schedule is the 
lowest risk for the subject—step (I)(a)–(b) of the above claim. The 
“direction of treatment” step takes place when the subject is 
immunized according to the more appropriate immunization 
schedule. However, take note of the divided infringement issues that 
could occur. One entity could easily conduct the screening step and 
another could conduct the immunization step. The patent could 
therefore be vulnerable to infringement with no recourse if the 
company did not take steps to ensure the implementation of their 
methods fit within the Limelight III framework. 
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B. Suggested Approaches to Drafting Personalized Medicine Claims 
Theoretically, a personalized medicine claim would be patent 
eligible as long as there is an active treatment step included during 
drafting.189 The claims deemed patent eligible in Classen,190 including 
a method of optimizing an immunization schedule and subsequent 
treatment of a patient, serve as examples of this concept.191 In 
comparison, “a claim drafted so broadly as to encompass the mere 
mental recognition of the existence of the biomarker correlated with 
a medically relevant physiological state will be found patent 
ineligible.”192 The claim deemed patent ineligible in Mayo—a method 
of determining the amount of a drug metabolite in the blood—serves 
as a cautionary tale of this concept.193 
When seeking to protect the many facets of a personalized 
medicine invention some argue that one should draft claims directed 
to any diagnostic assays, the optimized compound(s), and the 
method(s) of treatment.194 Assuming the client is a pharmaceutical 
company with near-limitless funds, this could be an acceptable 
approach. However, following the series of cases discussed in this 
Comment, some of these types of claims are far more likely than 
others to succeed. The difficulty associated with securing patents for 
diagnostic testing has discouraged researchers like Professor Rebecca 
Eisenberg who stated recently that “most important advances in 
[diagnostic testing] lie outside the boundaries of patent-eligible 
subject matter.”195 Nonetheless, Limelight III should have quelled 
similar concerns196—that directing claims to multiple actors by 
claiming diagnosis and treatment steps would lead to unenforceable 
patents—by relaxing the divided infringement standard.197 Therefore, 
because multi-step processes are more protectable under Limelight 
III, the following suggestions are directed primarily to the standard 
two-step personalized medicine patents with one initial exception. 
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1.  Start with Composition of Matter Patents 
First and foremost, patent drafters should not forget claims 
directed to the treatment itself. A composition of matter patent can 
be directed to a “composition of two or more substances and all 
composite articles, whether they be the result of chemical union, or of 
mechanical mixture, or whether they be gasses, fluids, powders or 
solids.”198 In the case of pharmaceutical patents, the key “composition 
of matter” is the active ingredient of the drug. Additionally, in the 
case of diagnostic methods, “claims to diagnostic assay reagents 
themselves may be [an] appropriate alternative way[] to protect the 
assay.”199 If the personalized medicine patent involves treatment with 
a new therapeutic, drafters should make sure to claim the drug itself 
separately. For example, the company that owns the cystic fibrosis 
drug Kalydeco,200 Vertex Pharmaceuticals, has patent applications 
filed for both the composition itself as well as methods of treatment 
using the composition.201 
However, one will need to be wary that said composition is not 
simply isolated from nature in its naturally occurring form. As 
discussed above with respect to a naturally occurring antibiotic, the 
current subject matter eligibility guidelines no longer allow the 
patenting of such substances without a significant change from its 
natural state.202 
2.  Strive for “Something More” 
As the differences between the Federal Circuit’s reasoning in 
Classen and Mayo are subtle,203 it is apparently necessary that drafters 
blatantly include the required “something more” in the patent 
claim.204 Thus, when drafting a method claim, drafters should consult 
the subject matter eligibility guidelines205 that include relevant factors 
that weigh toward and against eligibility. First and foremost, if 
drafters claim a process involving a judicial exception, drafters should 
ensure that the claim is not simply directed to the judicial exception, 
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so as to avoid foreclosing it from use by others.206 Ideally, drafters 
should try to ensure that the examiner will consider the steps 
mentioned in addition to the judicial exception to be “something 
more.”207 
Specifically, the examiner’s analysis will look to see if the claim 
recites limitations that qualify as “something more” or not. Factors 
that weigh in favor of eligibility include claims that are 
improvements to another technology or technical 
field;	.	.	.	effecting a transformation or reduction of a particular 
article to a different state or thing; adding a specific limitation 
other than what is well-understood, routine and conventional in 
the field, or adding unconventional steps that confine the claim 
to a particularly useful application; or other meaningful 
limitations beyond generally linking the use of the judicial 
exception to a particular technological environment.208 
Factors that weigh against eligibility include 
adding the words ‘apply it’	.	.	.	with the judicial exception	.	.	.	; 
simply appending well-understood and conventional activities 
previously known to the industry, specified at a high level of 
generality	.	.	.	; adding insignificant extrasolution activity to the 
judicial exception	.	.	.	; generally linking the use of the judicial 
exception to a particular	.	.	.	field of use.209 
However, including relevant factors that weigh in favor of 
eligibility may prove more easily said than done, as what the USPTO 
has considered “something more” has remained unclear. Although 
Sequenom petitioned the Supreme Court for certiorari,210 essentially 
in hopes of clarifying or overruling Mayo’s overly broad test,211 the 
 
 206. Id. at 2–3. The claims set forth in Diamond v. Diehr, 450 U.S. 175, 178–84 (1981), 
are some of the only eligible examples provided by the USPTO. The Court noted that 
because the claims were directed at a process of molding rubber and not the mathematical 
formula used in the process, the claims were patent eligible under 35 U.S.C. §	101. Id. at 
191. 
 207. March 2014 Guidelines supra note 46, at 3–4.  
 208. 2014 Interim Guidance on Patent Subject Matter Eligibility, 79 Fed. Reg. 74,618, 
74,624 (Dec. 16, 2014) (to be codified at 37 C.F.R. pt. 1). 
 209. Id. 
 210. Petition for a Writ of Certiorari, Sequenom v. Ariosa Diagnostics, Inc., No. 15-
1182 (U.S. Mar. 21, 2016), 2016 WL 1105544, cert. denied, 136 S. Ct. 2511 (2016).  
 211. Id. at *i. 
The question presented is: Whether a novel method is patent-eligible where: (1) a 
researcher is the first to discover a natural phenomenon; (2) that unique 
knowledge motivates him to apply a new combination of known techniques to that 
95 N.C. L. REV. 493 (2017) 
2017] PHARMACEUTICAL PATENTS 521 
petition was denied.212 Thus, patent drafters will need to continue 
erring on the side of caution. They will need to discuss with their 
clients if narrower patent claims, directed to more specific subject 
matter, are an acceptable solution to ensure that an indisputable 
“something more” has been added to the judicial exception. If not, 
the potential patent holder will either have these claims denied by the 
USPTO or risk having these patent invalidated during future 
infringement litigation. 
3.  Engage All of the Actors 
Personalized medicine is, by necessity, conducted among 
multiple actors. Technicians run the diagnostic tests. A doctor 
examines the patient and prescribes the drugs. The patients 
themselves may administer the drugs. Following the pro-patentee 
opinion in Limelight III,213 drafters must pay close attention to how 
the Federal Circuit defines both what constitutes direction and 
control of another’s performance and what is required to establish a 
joint enterprise.214 
Patent prosecutors need to carefully discuss with their clients 
how they plan to implement the patented method, using Eli Lilly & 
Co. v. Teva Parenteral Medicines, Inc.215 as an example. If the method 
will not be conducted in-house, or if a contractual or agency 
relationship does not exist with those implementing the method,216 the 
company will need make sure any use of the method will fall within 
the joint enterprise framework set forth in Limelight III. Thus, the 
patentee will need to establish one of the four elements of a joint 
enterprise: 
(1) an agreement, express or implied, among the members of 
the group; (2) a common purpose to be carried out by the 
group; (3) a community of pecuniary interest in that purpose, 
among the members; or (4) an equal right to a voice in the 
 
discovery; and (3) he thereby achieves a previously impossible result without 
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Id.  
 212. See Sequenom v. Ariosa Diagnostics, 136 S. Ct. 2511 (2016). 
 213. See supra Section III.B. 
 214. See Akami Techs., Inc. v. Limelight Networks, Inc., 797 F.3d 1020, 1023 (Fed. Cir. 
2015) (en banc).  
 215. 126 F. Supp. 3d. 1037, 1041–43 (S.D. Ind. 2015). 
 216. See Limelight Networks, Inc., 797 F.3d at 1023. 
95 N.C. L. REV. 493 (2017) 
522 NORTH CAROLINA LAW REVIEW [Vol. 95 
direction of the enterprise, which gives an equal right of 
control.217 
In sum, now that the standards for what constitutes direct 
infringement have been relaxed, patentees need to know of and 
exercise their right to protect their intellectual property. 
CONCLUSION 
Following the Supreme Court’s opinion in Limelight II, a 
multitude of commentators lamented the evisceration of medical 
treatment method patents. Decision after decision narrowing the so-
called “coarse filter” of patent eligible subject matter necessitating 
patents directed to unprotectable, complicated methods conducted by 
multiple actors was a recipe for disaster. While biotech patent 
eligibility under §	101 is still somewhat hit or miss, recent subject 
matter eligibility guidelines, publicly available Office actions, and 
case law provide some patent drafting help. One of the most likely 
means of overcoming an examiner’s declaration that a personalized 
medicine patent is directed to a judicial exception is to include an 
active treatment step, thus creating patent claims directed to a 
method of treatment. The Federal Circuit’s opinion in Limelight III 
allows for exactly that style of drafting without handing the 
technology off to the closest generic company, forgoing any available 
recourse. Thus, there is hope that the exciting field of personalized 
medicine will continue to evolve, spurred by advances in technology, 
hefty federal funding, and the promise that pharma investors can 
recoup the billions required for effective research and development. 
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